Catalyst Pharmaceuticals (CPRX) News Today $24.84 +0.57 (+2.35%) Closing price 05/2/2025 04:00 PM EasternExtended Trading$24.76 -0.07 (-0.30%) As of 05/2/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Price T Rowe Associates Inc. MD Has $25.37 Million Holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)Price T Rowe Associates Inc. MD lessened its holdings in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 1.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,215,438 sharesMay 3 at 4:28 AM | marketbeat.comCatalyst Pharmaceuticals (CPRX) to Release Earnings on WednesdayCatalyst Pharmaceuticals (NASDAQ:CPRX) will be releasing its Q1 2025 earnings after the market closes on Wednesday, May 7. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-7-catalyst-pharmaceuticals-inc-stock/)May 2 at 10:08 AM | marketbeat.comEnvestnet Asset Management Inc. Has $1.34 Million Stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)Envestnet Asset Management Inc. lifted its position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 162.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 64,395 shares of the biopharmaceutMay 2 at 3:26 AM | marketbeat.comBoothbay Fund Management LLC Cuts Holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)Boothbay Fund Management LLC lessened its stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 27.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 76,865 shares ofMay 1 at 5:57 AM | marketbeat.comCatalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Holdings Lifted by Tower Research Capital LLC TRCTower Research Capital LLC TRC increased its holdings in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 242.6% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 26,491 shareMay 1 at 4:34 AM | marketbeat.comIs Now The Time To Put Catalyst Pharmaceuticals (NASDAQ:CPRX) On Your Watchlist?April 30 at 5:32 PM | finance.yahoo.comCatalyst Pharmaceuticals to Participate in the BofA Securities Health Care Conference 2025April 30 at 8:03 AM | globenewswire.comJump Financial LLC Decreases Stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)Jump Financial LLC cut its holdings in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 59.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 14,074 shares of the biopharmaceutical company'April 29, 2025 | marketbeat.comWells Fargo & Company MN Sells 73,111 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)Wells Fargo & Company MN cut its holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 46.9% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 82,820 shares of the biopharmaceutical company's stock after selling 73,111 shApril 28, 2025 | marketbeat.comCatalyst Pharmaceuticals, Inc. (CPRX): Among Stocks with Consistent Growth to Buy NowApril 27, 2025 | msn.comCanada Pension Plan Investment Board Invests $1.24 Million in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)Canada Pension Plan Investment Board bought a new position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 59,600 shares of the biopharmaceutical company's stockApril 27, 2025 | marketbeat.comWalleye Capital LLC Sells 234,105 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)Walleye Capital LLC lessened its holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 94.3% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 14,183 shares of the biopharmaceutical companApril 27, 2025 | marketbeat.comFirst Trust Advisors LP Cuts Holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)First Trust Advisors LP decreased its position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 8.0% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 2,233,834 shares of the biopharmaceutical company's stock after selling 195,13April 26, 2025 | marketbeat.comCatalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Shares Sold by Marshall Wace LLPMarshall Wace LLP cut its stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 70.5% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 253,637 shares of the biopharmaceutical company's stock after selling 607,297 shares during the peApril 26, 2025 | marketbeat.comRaymond James Financial Inc. Purchases Shares of 329,980 Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)Raymond James Financial Inc. acquired a new position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 329,980 shares of the biophApril 26, 2025 | marketbeat.comBI Asset Management Fondsmaeglerselskab A S Purchases New Holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)BI Asset Management Fondsmaeglerselskab A S acquired a new position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) during the 4th quarter, according to its most recent 13F filing with the SEC. The fund acquired 116,758 shares of the biopharmaceutical company's stock, valuedApril 24, 2025 | marketbeat.comCatalyst Pharmaceuticals to Report First Quarter 2025 Financial Results on May 7, 2025April 22, 2025 | globenewswire.comMesirow Institutional Investment Management Inc. Decreases Stock Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)Mesirow Institutional Investment Management Inc. trimmed its position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 7.3% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 742,295 shares of the biopharmaceutical cApril 22, 2025 | marketbeat.comCatalyst Pharmaceuticals price target raised to $34 from $33 at BofAApril 22, 2025 | markets.businessinsider.comInvesco Ltd. Lowers Stock Holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)Invesco Ltd. cut its stake in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 9.9% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 846,851 shares of the biopharmaceutical company's stock aftApril 22, 2025 | marketbeat.comAltium Capital Management LLC Sells 130,000 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)Altium Capital Management LLC lessened its position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 33.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 255,000 shares of the biophaApril 20, 2025 | marketbeat.comCreativeOne Wealth LLC Makes New Investment in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)CreativeOne Wealth LLC acquired a new stake in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 36,694 shares of the biopharmaceutical cApril 20, 2025 | marketbeat.comLPL Financial LLC Buys 15,961 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)LPL Financial LLC lifted its stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 38.0% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 57,983 shares of the biopharmaceutical company's stock after acquiring an addiApril 20, 2025 | marketbeat.comEAM Investors LLC Cuts Stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)EAM Investors LLC cut its holdings in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 16.8% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 134,124 shares of the biopharmaceutical company's stock after sellApril 19, 2025 | marketbeat.comCiti Remains a Buy on Catalyst Pharma (CPRX)April 18, 2025 | markets.businessinsider.comCatalyst Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors despite daily gainsApril 17, 2025 | marketwatch.comLSV Asset Management Cuts Stock Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)LSV Asset Management decreased its holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 18.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 777,124 shares of the biopharmaceutical company's stock after selling 174,2April 15, 2025 | marketbeat.comFederated Hermes Inc. Purchases 120,249 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)Federated Hermes Inc. boosted its holdings in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 222.1% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 174,390 shApril 15, 2025 | marketbeat.comNorges Bank Invests $1.92 Million in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)Norges Bank purchased a new position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 91,770 shares of the biopharmaceutical coApril 14, 2025 | marketbeat.comJPMorgan Chase & Co. Has $15.36 Million Stock Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)JPMorgan Chase & Co. grew its holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 80.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 736,197 shares of the biopharmaceutical company's stock after acquiring an adApril 14, 2025 | marketbeat.comCatalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Shares Purchased by Martingale Asset Management L PMartingale Asset Management L P raised its stake in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 27.4% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 110,967 shares of the biopharmaceutical company's stock afApril 13, 2025 | marketbeat.comCatalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Given Consensus Rating of "Buy" by AnalystsShares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Get Free Report) have been given a consensus recommendation of "Buy" by the eight ratings firms that are currently covering the stock, MarketBeat.com reports. Seven research analysts have rated the stock with a buy rating and one has given aApril 13, 2025 | marketbeat.comKennedy Capital Management LLC Sells 23,750 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)Kennedy Capital Management LLC decreased its position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 2.3% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,017,666 shares of the biophApril 12, 2025 | marketbeat.comRenaissance Technologies LLC Increases Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)Renaissance Technologies LLC grew its stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 7.1% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,706,116 shares of the biopharmaceApril 12, 2025 | marketbeat.comIs Catalyst Pharmaceuticals, Inc. (CPRX) the Best Russell 2000 Stock to Buy According to Wall Street Analysts?April 11, 2025 | insidermonkey.comRenaissance Group LLC Invests $4.23 Million in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)Renaissance Group LLC bought a new stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 202,760 shares of the biopharmaceutical company's stockApril 10, 2025 | marketbeat.comCatalyst Pharmaceuticals (NasdaqCM:CPRX) Navigates Market Volatility With 3% DipApril 9, 2025 | finance.yahoo.comCatalyst Pharmaceuticals submits NDS to Health Canada for AgamreeApril 9, 2025 | markets.businessinsider.comCatalyst Pharmaceuticals announces Health Canada’s acceptance of AGAMREE NDSApril 9, 2025 | markets.businessinsider.comCatalyst Pharmaceuticals Announces Health Canada's Acceptance of AGAMREE® New Drug Submission with Priority Review for Sub-Licensee Kye PharmaceuticalsApril 8, 2025 | globenewswire.comVanguard Group Inc. Grows Stock Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)Vanguard Group Inc. lifted its holdings in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 4.9% during the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 8,431,094 shares of the biopharmaceutical company's stock after acquiring an additiApril 8, 2025 | marketbeat.comAmerican Century Companies Inc. Grows Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)American Century Companies Inc. boosted its position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 18.3% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 157,409 shares of the biopharmaceutApril 8, 2025 | marketbeat.comTrexquant Investment LP Sells 89,171 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)Trexquant Investment LP reduced its position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 30.2% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 206,489 shares of the biopharmaceutApril 7, 2025 | marketbeat.comArrowstreet Capital Limited Partnership Purchases 396,506 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)Arrowstreet Capital Limited Partnership increased its position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 131.4% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 698,152 sharApril 6, 2025 | marketbeat.comCatalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Shares Bought by Sei Investments Co.Sei Investments Co. grew its position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 14.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 116,318 shares of the biopharmaceutical compaApril 6, 2025 | marketbeat.comBryce Point Capital LLC Purchases Shares of 54,358 Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)Bryce Point Capital LLC acquired a new position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 54,358 shares of the biopharmaceutical company's stoApril 5, 2025 | marketbeat.comWhat Makes Catalyst Pharmaceuticals (CPRX) an Investment Choice?April 4, 2025 | finance.yahoo.comCatalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Shares Bought by Commonwealth Equity Services LLCCommonwealth Equity Services LLC increased its position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 133.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 39,331 shares of the bApril 4, 2025 | marketbeat.comWhy a Clutch of Pharmaceutical and Biotech Stocks Escaped the Market's Swoon on ThursdayApril 3, 2025 | fool.comKLP Kapitalforvaltning AS Invests $772,000 in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)KLP Kapitalforvaltning AS bought a new stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 37,000 shares of the biopharmaceutical compApril 2, 2025 | marketbeat.com Get Catalyst Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CPRX and its competitors with MarketBeat's FREE daily newsletter. Email Address CPRX Media Mentions By Week CPRX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CPRX News Sentiment▼1.260.58▲Average Medical News Sentiment CPRX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CPRX Articles This Week▼126▲CPRX Articles Average Week Get Catalyst Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CPRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies MRNA News ASND News VTRS News QGEN News ROIV News RVMD News LNTH News BBIO News TGTX News LEGN News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CPRX) was last updated on 5/3/2025 by MarketBeat.com Staff From Our PartnersThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredWhat President Trump’s Executive Order 14154 means for your moneyNearly $3 trillion disappeared from the stock market on Thursday morning. According to Whitney Tilson - a f...Stansberry Research | SponsoredHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredMost traders are panicking. We’re cashing inMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Catalyst Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Catalyst Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CPRX Stock Free CPRX Stock Alerts